You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 德琪醫藥-B升超4% 希維奧二線治療方案獲納入澳大利亞藥品福利計劃
格隆匯 06-05 10:04
格隆匯6月5日丨德琪醫藥(6996.HK)升4.37%,報1.91港元,總市值12億港元。近日公司宣佈其希維奧(塞利尼索片)聯合硼替佐米及地塞米松塞(XVd方案)獲澳大利亞藥品福利計劃(PBS)收錄,這是希維奧再次獲PBS收錄。希維奧是全球首個全新機制的口服選擇性核輸出蛋白(XPO1)抑制劑,也是首款且唯一一款獲澳大利亞藥品管理局(TGA)批准用於治療復發/難治性多發性骨髓瘤(R/R MM)以及三類藥物難治的R/R MM患者的選擇性核輸出抑制劑(SINE)。III期BOSTON研究數據顯示,XVd方案對於細胞遺傳學狀態為高危的患者尤為其有效。 目前,希維奧(塞利尼索片)已獲得中國大陸、中國台灣、韓國、新加坡和澳大利亞的新藥上市批准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account